Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure

Circulation

Volumn 91, Issue 6, 1995, Pages 1824-1833

  Nascimben, Luigino ^a   Friedrich, Jan ^a   Liao, Ronglih ^b   Pauletto, Paolo ^c   Pessina, Achille C ^c   Ingwall, Joanne S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

cardiomyopathy; creatine kinase; enalapril; spectroscopy

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CREATINE; CREATINE KINASE ISOENZYME; CREATINE PHOSPHATE; ENALAPRIL; PHOSPHORUS 31;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALCULATION; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; HEART CONTRACTION; HEART PERFORMANCE; HEART WEIGHT; ISOLATED HEART; MALE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SYRIAN HAMSTER;

EID: 0028966882     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.91.6.1824     Document Type: Article

References (38)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and con-gestive heart failure. N Engl J Med. 1991;325:293-302.
3. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation. 1993;88(pt 1): 2277-2283.
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
5. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, Tillisch JH, Walden JA, Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19:842-850.
6. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986;31:198-248.
7. Fonarow GC, Stevenson LW. Angiotensin-converting enzyme inhibition in heart failure. In: Singh BN, ed. Cardiovascular Pharmacology and Therapeutics. New York, NY: Churchill Livingstone; 1994:797-814.
8. Camacho SA, Wikman-Coffelt J, Wu ST, Watters TA, Botvinick EH, Sievers R, James TL, Jasmin G, Parmley WW. Improvement in myocardial performance without a decrease in high-energy phosphate metabolites after isoproterenol in Syrian cardiomyopathic hamsters. Circulation. 1988;77:712-719.
9. Haleen SJ, Weishaar RE, Overhiser RW, Bousley RF, Keiser JA, Rapundalo SR, Taylor DG. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathy hamster. Circ Res. 1991;68:1302-1312.
10. 31P NMR magnetization transfer study. J Biol Chem. 1985;260:3512-3517.
11. Nascimben L, Pauletto P, Pessina AC, Reis I, Ingwall JS. Decreased energy reserve may cause pump failure in human dilated cardiomyopathy. Circulation. 1991;84(suppl II):II-563. Abstract.
12. 31P magnetic resonance spectroscopy. Lancet. 1991;338:973-976.
13. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J. 1991;122:795-801.
14. Ingwall JS. Is cardiac failure a consequence of decreased energy reserve? Circulation. 1993;87(suppl VII):VII-58-VII-62.
15. Scheuer J. Metabolic factors in myocardial failure. Circulation. 1993;87(suppl VII):VII-54-VII-57.
16. Childs TJ, Adams MA, Mak AS. Regression of cardiac hypertrophy in spontaneously hypertensive rats by enalapril and the expression of contractile proteins. Hypertension. 1990;16:662-668.
17. Lowry OH, Rosebrough MJ, Farr AL, Randall RJ. Protein measurement with the Folin reagent. J Biol Chem. 1951;193:265-275.
18. Kammermeier H. Microassay of free and total creatine from tissue extracts by combination of chromatographic and fluorometric methods. Anal Biochem. 1973;56:341-345.
19. Rosalki SP. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med. 1967;69:696-705.
20. Hall NF, DeLuca M. Electrophoretic separation and quamitation of creatine kinase isozymes. Anal Biochem. 1976;76:561-567.
21. Basson CT, Grace AM, Roberts R. Enzyme kinetics of a highly purified mitochondrial creatine kinase in comparison with cytosolic forms. Mol Cell Biochem. 1985;67:151-159.
22. Bak MI, Ingwall JS. NMR-invisible ATP in heart: fact or fiction? Am J Physiol. 1992;262(Enidocrinol Metab 25):E943-E947.
23. 1 measurements with and without exchange in the heart. Magn Reson Med. 1993;30:45-50.
24. Polimeni PI. Measurement of myocardial electrolyte distributions. Tech Life Sci Cardiovasc Physiol. 1984;317:1-34.
25. Jalil JE, Doering CW, Janicki JS, Pick R, Clark WA, Weber KT. Structural vs. contractile protein remodelling and myocardial stiffness in hypertrophied rat left ventricle. J Mol Cell Cardiol. 1988;20:1179-1187.
26. Gertz FW. Cardiomyopathic Syrian hamster: a possible model of human disease. Prog Exp Tumor Res. 1972;16:242-260.
27. Veech RL, Lawson JWR, Cornell NW, Krebs HA. Cytosolic phosphorylation potential. J Biol Chem. 1979;254:6538-6547.
28. Forsen S, Hoffman RA. Study of moderately rapid chemical exchange reactions by means of nuclear magnetic double resonance. J Chem Phys. 1963;39:2892-2901.
29. Morrison JF, Cleland WW. Isotope exchange studies of the mechanism of the reaction catalyzed by adenosine triphosphate: creatine phosphotransferase. J Biol Chem. 1966;241:673-683.
30. McAuliffe JJ, Perry SB, Brooks EE, Ingwall JS. Kinetics of the creatine kinase reaction in neonatal rabbit heart: an empirical analysis of the rate equation. Biochemistry. 1991;30:2585-2593.
31. Bittl JA, Ingwall JS. Intracellular high-energy phosphate turnover in normal and hypertrophied myocardium. Circulation. 1987; 75(suppl I):I-96-I-101.
32. Khuchua ZA, Ventura-Clapier R, Kuznetsov AV, Grishin MN, Saks VA. Alterations in the creatine kinase system in the myocardium of cardiomyopathic hamsters. Biochem Biophys Res Commun. 1989;165:748-757.
33. Zweier JL, Jacobus WE, Korecky B, Brandeis-Barry Y. Bioenergetic consequences of cardiac phosphocreatine depletion induced by creatine analogue feeding. J Biol Chem. 1991;266: 20296-20304.
34. Hamman BL, Bittl JA, Jacobus WE, Ingwall JS. Inhibition of creatine kinase decreases the contractile reserve of the isolated rat heart. Am J Physiol. In press.
35. van Deursen J, Heerschap A, Oerlemans F, Ruitenbeek W, Jap P, ter Laak H, Wieringa B. Skeletal muscles of mice deficient in muscle creatine kinase lack burst activity. Cell. 1993;74:621-631.
36. 31P NMR surface coil studies in brain, heart, and skeletal muscle of the living rat. Biochemistry. 1987;26:6083-6090.
37. 31P-NMR surface coil studies in living rat. Circ Res. 1987;60:871-878.
38. 31P magnetization transfer studies. In: Smirnoff VN, Katz A, eds. Proc 6th Joint USA-USSR Symposium on Myocardial Metabolism. New York, NY: Gordon and Breach; 1987:3-48.